A number of studies have indicated that patients with EGFR-mutated NSCLC undergoing osimertinib treatment may be susceptible to developing interstitial lung disease (ILD), which can potentially lead to treatment interruptions, medication adjustments, and even jeopardise the patient’s life safety (Gemma et al., 2020). This evidence concerns the gene EGFR and non-small cell lung carcinoma.